APPENDICURE
Innovations in the Treatment of Appendix Cancer
Category: Resource
Resource
-
If you live with pseudomyxoma peritonei, or love someone who does, you already know the central strangeness of it. The pathology reports use words like “low grade.” The tumors do not divide quickly. And yet the disease keeps producing mucin, year after year, surgery after surgery, until the abdomen cannot hold any more. This is…
-
For the past several weeks, I have been collecting information from patients in our community who are taking Ibrance, Verzenio, or Kisqali for appendix cancer. The drugs are called CDK4/6 inhibitors. They are FDA-approved for breast cancer. They are not FDA-approved for our disease. And yet, at major cancer centers around the country, oncologists are…
-
Why a patient asking “is this actually a plan?” is asking the right question, and what the published protocols say. This post was already drafted. I had been chipping away at it for a few days because I keep hearing different versions of the same frustration from LAMN patients, and I had not yet seen…
-
And why submitting your data to the Patient-Led Global Appendix Cancer Registry is one of the most important things you can do right now If you are living with high-grade appendix cancer, goblet cell adenocarcinoma (GCA), signet ring cell carcinoma, or another aggressive subtype, you already know what the data does not yet show. You…
-
What Appendix Cancer Patients Should Know If you or someone you love is facing CRS HIPEC surgery, you already understand this is not a routine procedure. It is one of the most complex operations in cancer care and often one of the most important decisions a patient will make. A question that comes up again…